Literature DB >> 21197188

American society of clinical oncology clinical practice guideline update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.

Harold J Burstein1, Jennifer J Griggs, Ann A Prestrud, Sarah Temin.   

Abstract

ASCO's technology assessment of the use of aromatase inhibitors in the adjuvant setting was last updated in 2004. ASCO's Update Committee on Aromatase Inhibitors reconvened in May 2009 to update this guideline.

Entities:  

Year:  2010        PMID： 21197188      PMCID： PMC2936467          DOI： 10.1200/JOP.000082

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN： 1554-7477            Impact factor:   3.840


  1 in total

Review 1.  American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.

Authors:  Harold J Burstein; Ann Alexis Prestrud; Jerome Seidenfeld; Holly Anderson; Thomas A Buchholz; Nancy E Davidson; Karen E Gelmon; Sharon H Giordano; Clifford A Hudis; Jennifer Malin; Eleftherios P Mamounas; Diana Rowden; Alexander J Solky; Maryfran R Sowers; Vered Stearns; Eric P Winer; Mark R Somerfield; Jennifer J Griggs
Journal:  J Clin Oncol       Date:  2010-07-12       Impact factor: 44.544
  1 in total
  29 in total

1.  Aromatase inhibitor associated arthralgia: the importance of oncology provider-patient communication about side effects and potential management through physical activity.

Authors:  Kirsten A Nyrop; Leigh F Callahan; Christine Rini; Mary Altpeter; Betsy Hackney; Amy DePue; Anne Wilson; Arielle Schechter; Hyman B Muss
Journal:  Support Care Cancer       Date:  2016-01-12       Impact factor: 3.603

2.  Long-term oral bisphosphonate use in relation to fracture risk in postmenopausal women with breast cancer: findings from the Women's Health Initiative.

Authors:  Rebecca L Drieling; Andrea Z LaCroix; Shirley A A Beresford; Denise M Boudreau; Charles Kooperberg; Rowan T Chlebowski; Margery Gass; Carolyn J Crandall; Catherine R Womack; Susan R Heckbert
Journal:  Menopause       Date:  2016-11       Impact factor: 2.953

3.  Post-chemotherapy serum anti-müllerian hormone level predicts ovarian function recovery.

Authors:  Hyun-Ah Kim; Jihye Choi; Chan Sub Park; Min-Ki Seong; Sungeun Hong; Jae-Sung Kim; In-Chul Park; Jin Kyung Lee; Woo Chul Noh
Journal:  Endocr Connect       Date:  2018-07-16       Impact factor: 3.335

Review 4.  Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review.

Authors:  Caitlin C Murphy; L Kay Bartholomew; Melissa Y Carpentier; Shirley M Bluethmann; Sally W Vernon
Journal:  Breast Cancer Res Treat       Date:  2012-06-12       Impact factor: 4.872

Review 5.  Cancer Treatment-Induced Bone Loss in women with breast cancer.

Authors:  Peyman Hadji
Journal:  Bonekey Rep       Date:  2015-05-20

6.  The effect of Medicaid expansion on prescriptions for breast cancer hormonal therapy medications.

Authors:  Johanna Catherine Maclean; Michael T Halpern; Steven C Hill; Michael F Pesko
Journal:  Health Serv Res       Date:  2020-04-17       Impact factor: 3.402

7.  CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8.

Authors:  Matthew P Goetz; Vera J Suman; Tanya L Hoskin; Michael Gnant; Martin Filipits; Stephanie L Safgren; Mary Kuffel; Raimund Jakesz; Margaretha Rudas; Richard Greil; Otto Dietze; Alois Lang; Felix Offner; Carol A Reynolds; Richard M Weinshilboum; Matthew M Ames; James N Ingle
Journal:  Clin Cancer Res       Date:  2012-12-04       Impact factor: 12.531

8.  Genomic Testing in the Management of Early-Stage Breast Cancer.

Authors:  Sima Ehsani; Kari Braun Wisinski
Journal:  J Clin Outcomes Manag       Date:  2017-05

Review 9.  Immuno-Oncology Medicines: Policy Implications and Economic Considerations.

Authors:  Georges Adunlin; Stefanie P Ferreri; Jenny Dong; Maisha Kelly Freeman
Journal:  Innov Pharm       Date:  2019-08-08

10.  DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival.

Authors:  Liam Cornell; Joanne M Munck; Clara Alsinet; Augusto Villanueva; Laura Ogle; Catherine E Willoughby; Despina Televantou; Huw D Thomas; Jennifer Jackson; Alastair D Burt; David Newell; John Rose; Derek M Manas; Geoffrey I Shapiro; Nicola J Curtin; Helen L Reeves
Journal:  Clin Cancer Res       Date:  2014-12-05       Impact factor: 12.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.